MitrAssist Completes Raise of $1 Million

News of MitrAssist’s raise appeared in more than 235 global media outlets (newspapers, trade publications, news and information services).

TEL AVIV, Israel, July 1, 2013 /PRNewswire/ — MitrAssist, a portfolio company of The Trendlines Group’s Misgav Venture Accelerator, recently completed a raise of $1 million from angel investors and a multinational private strategic investor. The company set out to raise $600,000 in April this year and, due to overwhelming response, substantially exceeded their raise target.

MitrAssist has developed a minimally invasive approach to treating Mitral Regurgitation (MR), a disorder of the heart in which the mitral valve does not close properly when the heart pumps out blood. Annually, 250,000 people in the United States are diagnosed with MR. MitrAssist’s proprietary implant is placed on top of the heart’s own mitral valve and works in unison with it to enhance the valve’s functionality.

This “valve-in-valve” approach brings an improved, safe, cost-effective treatment solution for all MR patients, especially patients who are unsuitable for open-heart surgery, the only current solution. The company’s novel system offers a number of significant advantages: it preserves the natural mitral valve functionality, has minimal effect on heart physiology, conforms to any anatomical shape, and is designed for long-lasting results. It is also easy to implant and dramatically decreases the length of the procedure and patients’ recovery time. The company has a patent pending.

Read the full press release on The Wall Street Journal.

 

News about MitrAssist’s raise also appeared in Globes.
Heart valve implant co MitrAssist raises $1m (July 1, 2013)

Leave a Reply